Literature DB >> 12972475

Salivary gland scintigraphy in Sjögren's syndrome and patients with sicca symptoms but without Sjögren's syndrome: the psychological profiles and predictors for salivary gland dysfunction.

E-K Tensing1, D C Nordström, S Solovieva, K-O Schauman, I Sippo-Tujunen, T Helve, S Natah, J Ma, T F Li, Y T Konttinen.   

Abstract

OBJECTIVE: To characterise the psychological profiles of Sjögren's syndrome (SS) and patients with sicca symptoms but without SS; to find predictors for salivary gland function; to evaluate salivary scintigraphy as a method to differentiate between SS and patients with sicca symptoms but without SS. PATIENTS AND METHODS: Psychological tests (Medical Outcomes Study Short Form General Health Survey (SF-36), Jenkins Activity Survey, Toronto Alexithymia Scale, and Maastricht Questionnaire for vital exhaustion) were performed and assessment of the function of the salivary glands made in 26 patients with primary SS, 8 with secondary SS, and 9 with sicca symptoms but without SS. Data were analysed with BMDP new system version 1.0 statistical program.
RESULTS: Psychological profiles were similar in all groups. Hb, RF, ANA, and SSA differentiated between the groups. Results of salivary scintigraphy were predicted to 51% by ANA, SSA, SSB, IgG, IgA, diagnosis, vitality, and role limitations due to emotional problems. No predictors were found for the resting salivary flow. Salivary scintigraphy was pathological in 21/26 (81%) and in 8/8 (100%) patients with secondary SS, but only in 2/9 (22%) patients with sicca symptoms without SS (p=0.002) (sensitivity 85.3%, specificity 77.8%).
CONCLUSIONS: Patients with sicca symptoms but without SS have sickness behaviour similar to that of patients with SS. The results of salivary scintigraphy can be predicted by diagnosis and autoimmune findings; psychological characteristics added 20% to this predictive value. Distinction between SS and patients with sicca symptoms but without SS is difficult, but in addition to autoantibodies, salivary scintigraphy can be used for this purpose.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12972475      PMCID: PMC1754342          DOI: 10.1136/ard.62.10.964

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  51 in total

1.  Alexithymia in primary health care patients.

Authors:  M Joukamaa; B Sohlman; V Lehtinen
Journal:  J Psychosom Res       Date:  1995-10       Impact factor: 3.006

2.  Scintigraphy of the salivary glands in Sjögen's syndrome.

Authors:  J P Arrago; J D Rain; C Brocheriou; F Rocher
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

3.  Morphometric study of salivary glands in primary Sjögren's syndrome.

Authors:  P Manganelli; F Salaffi; A Nervetti; N Raffaini; G Olivetti
Journal:  Clin Exp Rheumatol       Date:  1989 May-Jun       Impact factor: 4.473

4.  A questionnaire to assess premonitory symptoms of myocardial infarction.

Authors:  A Appels; P Höppener; P Mulder
Journal:  Int J Cardiol       Date:  1987-10       Impact factor: 4.164

5.  Scintigraphic evaluation of the salivary glands in patients with Sjögren's syndrome.

Authors:  T Sugihara; Y Yoshimura
Journal:  Int J Oral Maxillofac Surg       Date:  1988-04       Impact factor: 2.789

6.  Hostility and the progression of carotid atherosclerosis.

Authors:  J Julkunen; R Salonen; G A Kaplan; M A Chesney; J T Salonen
Journal:  Psychosom Med       Date:  1994 Nov-Dec       Impact factor: 4.312

7.  Methotrexate in primary Sjögren's syndrome.

Authors:  F N Skopouli; P Jagiello; N Tsifetaki; H M Moutsopoulos
Journal:  Clin Exp Rheumatol       Date:  1996 Sep-Oct       Impact factor: 4.473

8.  Development and evaluation of the Oral Health Impact Profile.

Authors:  G D Slade; A J Spencer
Journal:  Community Dent Health       Date:  1994-03       Impact factor: 1.349

9.  Criterion validity of the Toronto Alexithymia Scale.

Authors:  G J Taylor; R M Bagby; D P Ryan; J D Parker; K F Doody; P Keefe
Journal:  Psychosom Med       Date:  1988 Sep-Oct       Impact factor: 4.312

10.  Type A behaviour pattern in Finland.

Authors:  A Reunanen; O Hanses; J Maatela; O Impivaara; A Aromaa
Journal:  Ann Clin Res       Date:  1987
View more
  5 in total

1.  Semi-quantitative evaluation of salivary gland function in Sjögren's syndrome using salivary gland scintigraphy.

Authors:  Qiong Zou; Ju Jiao; Min-Hong Zou; Jie-Hua Xu; Yun-Feng Pan; Jian-Ning Chen; Mu-Hua Cheng; Feng Zhang; Yong Zhang
Journal:  Clin Rheumatol       Date:  2012-09-02       Impact factor: 2.980

2.  High Prevalence of Thyroid Disease and Role of Salivary Gland Scintigraphy in Patients with Xerostomia.

Authors:  Ji-Hoon Jung; Chang-Hee Lee; Seung Hyun Son; Ju Hye Jeong; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Nucl Med Mol Imaging       Date:  2016-11-24

3.  Correlations between salivary gland scintigraphy and histopathologic data of salivary glands in patients with primary Sjogren's syndrome.

Authors:  Ji-Won Kim; Roh Jin; Jae Ho Han; Jeong-Hyun Kang; Ju-Yang Jung; Chang-Hee Suh; Young-Sil An; Hyoun-Ah Kim
Journal:  Clin Rheumatol       Date:  2022-06-30       Impact factor: 3.650

4.  Use of the European preliminary criteria, the Breiman-classification tree and the American-European criteria for diagnosis of primary Sjögren's Syndrome in daily practice: a retrospective analysis.

Authors:  C Langegger; M Wenger; C Duftner; C Dejaco; I Baldissera; R Moncayo; M Schirmer
Journal:  Rheumatol Int       Date:  2007-01-25       Impact factor: 3.580

5.  Can the function of the tubarial glands be evaluated using [99mTc]pertechnetate SPECT/CT, [18F]FDG PET/CT, and [11C]methionine PET/CT?

Authors:  Yohji Matsusaka; Tomohiko Yamane; Kenji Fukushima; Akira Seto; Ichiro Matsunari; Ichiei Kuji
Journal:  EJNMMI Res       Date:  2021-03-31       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.